IDT Biologika

IDT Biologika is a century-old, privately-held German CDMO with a strong focus on complex biologics, particularly live virus products and viral vectors. It operates as a full-service partner offering end-to-end solutions from process development to commercial-scale drug substance manufacturing and aseptic fill-finish across two BSL-2 certified sites. With significant regulatory approvals (EMA, FDA) and over €600 million invested in its facilities since 1993, the company is positioned as a key player in the growing outsourced manufacturing market for vaccines and advanced therapies. Its deep historical expertise in virology provides a distinct competitive advantage in the cell and gene therapy space.

BSL-2 facilities for live virus and viral vector manufacturing; broad upstream (cell culture, fermentation 200L-2000L) and downstream processing expertise; aseptic liquid and lyophilized fill-finish for vials and syringes; comprehensive analytical development.

IDT competes with large, diversified CDMOs like Lonza, Catalent, and Samsung Biologics, as well as specialized players in viral vector manufacturing (e.g., Oxford Biomedica, Charles River). Its key differentiators are its century of virology experience, integrated end-to-end services for live agents, and strong regulatory track record within its BSL-2 niche.